Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera

被引:0
|
作者
Lawoko, AL
Johansson, B
Hjalmarsson, S
Christensson, B
Ljungberg, B
Al-Khalili, L
Sjölund, M
Pipkorn, R
Fenyö, EM
Blomberg, J
机构
[1] Univ Lund, Dept Med Microbiol, Sect Virol, Lund, Sweden
[2] Uppsala Univ, Dept Med Sci, Sect Virol, Uppsala, Sweden
[3] Cent Hosp, Dept Infect Dis, Helsingborg, Sweden
[4] Univ Lund Hosp, Dept Infect Dis, S-22185 Lund, Sweden
[5] Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany
[6] Karolinska Inst, Microbiol & Tumorbiol Ctr, Stockholm, Sweden
关键词
anti-V3 IgG peptide ELISA; neutralisation in vitro; V3; sequences;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
IgG binding to V3 peptides and serum neutralising responses were studied in four HIV-1 infected individuals with progressive disease over a period of 31-70 months. The 18-20 mer pep tides comprised residues 299-317 (numbering of HIV1 MN) in the N-terminal half of the V3 loop of the envelope glycoprotein gp120 and were derived from the sequences of autologous, as well as heterologous isolates. All four individuals studied lacked anti-V3 IgG binding to at least one autologous V3 sequence. V3 peptides to which autologous sera lacked binding IgG were all immunogenic in rabbits and induced antisera that were broadly cross-reactive by EIA and broadly cross-neutralising to primary HIV-1 isolates. This indicates that the peptides are immunogenic per se and that the respective human hosts have selective defects in recognising the corresponding V3 sequences. Despite the absence of antibody binding to autologous V3 peptides, the human sera had neutralising antibodies to autologous (three out of four cases), as well as heterologous isolates (all cases). Moreover, in vitro exposure of the patients' isolates to autologous neutralising serum or the homologous rabbit antiserum selected for variants with amino acid substitutions close to the crown of the V3 loop or in regions outside the sequence corresponding to peptides used for immunisation. The amino acid exchanges affected V3 positions known to be antigenic and which are also prone to change successively in infected persons. It is likely that neutralising antibodies recognise both linear and conformational epitopes in the V3 loop. Apparently, there are several, but restricted, numbers of ways for this structure to change its conformation and thereby give rise to neutralisation resistant viruses. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码:169 / 179
页数:11
相关论文
共 50 条
  • [1] A BROADLY REACTIVE HUMAN ANTI-V3 MONOCLONAL-ANTIBODY EFFECTIVELY NEUTRALIZES PRIMARY HIV-1 ISOLATES
    GORNY, M
    WILLIAMS, C
    ZOLLAPAZNER, S
    OSSORIO, M
    BANSAL, G
    KOENIG, S
    CONLEY, AJ
    KESSLER, JA
    BOOTS, LJ
    LINEBERGER, D
    SCHLEIF, WA
    EMINI, EA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S34 - S34
  • [2] Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates
    Candotti, D
    Rosenheim, M
    Huraux, JM
    Agut, H
    JOURNAL OF VIROLOGICAL METHODS, 1997, 64 (01) : 81 - 93
  • [3] Anti-IgG antibodies from sera of healthy individuals neutralize HIV-1 primary isolates
    Metlas, Radmila
    Srdic, Tanja
    Vejkovic, Veljko
    CURRENT HIV RESEARCH, 2007, 5 (02) : 261 - 265
  • [4] EXPRESSION, PURIFICATION AND CHARACTERIZATION OF ANTI-V3 HUMAN SCFVS AGAINST HIV-1 CLADE C
    Kumar, R.
    Andrabi, R.
    Tiwari, A.
    Wig, N.
    Sinha, S.
    Luthra, K.
    SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 : A84 - A84
  • [5] Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    Almond, David
    Krachmarov, Chavdar
    Swetnam, James
    Zolla-Pazner, Susan
    Cardozo, Timothy
    ADVANCES IN VIROLOGY, 2012, 2012
  • [6] A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
    Rajesh Kumar
    Raiees Andrabi
    Ashutosh Tiwari
    Somi Sankaran Prakash
    Naveet Wig
    Durgashree Dutta
    Anurag Sankhyan
    Lubina Khan
    Subrata Sinha
    Kalpana Luthra
    BMC Biotechnology, 12
  • [7] A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C
    Kumar, Rajesh
    Andrabi, Raiees
    Tiwari, Ashutosh
    Prakash, Somi Sankaran
    Wig, Naveet
    Dutta, Durgashree
    Sankhyan, Anurag
    Khan, Lubina
    Sinha, Subrata
    Luthra, Kalpana
    BMC BIOTECHNOLOGY, 2012, 12
  • [8] Structural Basis of the Antibody-Antigen Interaction in Human Anti-V3 HIV-1 Monoclonal Antibodies
    Jiang, X.
    Burke, V.
    Williams, C.
    Gorny, M. K.
    Zolla-Pazner, S.
    Kong, X.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 11 - 11
  • [9] Genetically engineered HIV type 1 peptides as tools for the determination of anti-V3 loop antibody titers in sera from HIV type 1-infected patients
    vonBrunn, A
    Reichhuber, C
    Pfaff, E
    Wizemann, H
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (12) : 1459 - 1465
  • [10] An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera
    Gómez, CE
    López-Campistrous, AE
    Duarte, CA
    JOURNAL OF VIROLOGICAL METHODS, 1998, 71 (01) : 7 - 16